Shares in Ocular Therapeutix (NSDQ:OCUL) rose this week after the company topped expectations on Wall Street with its second-quarter financial results.
The Bedford, Mass.-based company posted a net loss of -$13.8 million on sales of $648,000 for the three months ended June 30, representing sales growth of 48% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.